Newsfeeds - Spark Newswire

1 minute read

Earnings

A Preview Of Exact Sciences’s Earnings

February 21, 10:11 AM

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-02-22. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.04.

EXAS

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

February 20, 9:06 AM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

February 18, 1:36 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

2 minute read

How Have Cathie Wood’s Top 10 Investments Performed In The Last 6 Months?

By AJ Fabino

February 17, 4:14 PM

Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020, beating the Nasdaq's 43.6% return.

ARKK

1 minute read

FDA
News

Exact Sciences Granted FDA Emergency Use Authorization For COVID-Flu Multiplex Assay

By Benzinga Newsdesk

February 16, 2:48 PM

https://www.fda.gov/media/150558/download

EXAS

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

January 20, 2:19 PM

ABMD

2 minute read

FDA
News

Exact Sciences Presents Data On Accuracy Of Second-Generation Cologuard Test, Progress Toward An Even Better Colorectal Cancer Screening Solution For Patients

By Benzinga Newsdesk

January 18, 6:20 PM

Exact Sciences Corp. (NASDAQ:EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at

EXAS

2 minute read

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?

By Chris Katje

January 14, 5:32 PM

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With the funds falling over the past year and hitting new lows, Benzinga asked which fund would be favored to buy and hold.

ARKF